Division of Novartis AG
Latest From Endocyte Inc.
In an interview at Novartis' research campus in Cambridge, Mass., Schaffert spoke about the upcoming launch of Piqray for breast cancer, building in radiopharmaceuticals, Kymriah's ongoing manufacturing challenges and more.
Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling on the market, Novartis is paying $3.4bn upfront to buy Xiidra.
The number of US drug approvals in 2018 was striking, but most of the novel products launched last year are for rare diseases or niche cancers, meaning commercial success may be in the eye of the beholder.
R&D head John Tsai spoke with Scrip about culture change at Novartis as it moves toward advanced therapy platforms and embraces digital technologies, and offered a peek into what’s in store for R&D in 2019 and beyond.
- In Vitro Diagnostics
- Diagnostic Imaging Equipment & Supplies
- Drug Delivery
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Novartis AG
- Senior Management
Michael A Sherman, Pres. & CEO
Michael T Andriole, CFO
Matthew Call, VP, Bus. Dev. & Mktg.
Philip S Low, PhD, CSO
Alison A Armour, MD, CMO
- Contact Info
Phone: (765) 463-7175
3000 Kent Ave.
West Lafayette, IN 47906
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.